Welcome to our dedicated page for Tscan Therapeutics SEC filings (Ticker: TCRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The TScan Therapeutics, Inc. (TCRX) SEC filings page on Stock Titan provides access to the company’s regulatory documents as filed with the U.S. Securities and Exchange Commission. TScan is a clinical-stage biotechnology company listed on The Nasdaq Global Market, and its filings offer detailed insight into its T cell receptor-engineered T cell (TCR-T) therapy programs, financial condition, and corporate governance.
For TCRX, key filings include current reports on Form 8-K that describe material events such as clinical and regulatory milestones for TSC-101 in the ALLOHA™ Phase 1 heme trial, strategic prioritization of the hematologic malignancies program, pauses in solid tumor trial enrollment, and updates on in vivo engineering and autoimmunity research. Other 8-Ks address financial results, workforce changes, executive appointments, and stockholder meeting outcomes. These documents help readers understand how TScan is advancing its heme and solid tumor programs, implementing a commercial-ready manufacturing process, and managing its operating runway.
Investors can also use this page to locate annual and quarterly reports (Forms 10-K and 10-Q) when available, which typically contain comprehensive discussions of TScan’s pipeline, risk factors, and financial statements. In addition, filings related to equity compensation plans, retention programs for key executives, and stockholder votes provide visibility into compensation structures and governance practices.
Stock Titan enhances access to TCRX filings by offering real-time updates from EDGAR and AI-powered summaries that explain the significance of each document in straightforward language. Users can quickly scan for information on clinical trial plans, cash runway disclosures, strategic shifts between heme, solid tumor, and autoimmunity efforts, and other developments that shape TScan Therapeutics’ profile as a public biotechnology company.
TScan Therapeutics reported third-quarter results, highlighting collaboration revenue and continued investment in its TCR-T pipeline. Q3 2025 collaboration and license revenue was $2.5 million, while research and development expense reached $31.7 million and general and administrative expense was $7.9 million. The company recorded a net loss of $35.7 million.
As of September 30, 2025, cash, cash equivalents and marketable securities totaled $184.5 million, and long‑term debt was $32.4 million. Year to date, revenue was $7.8 million, primarily from the Amgen collaboration.
After aligning with the FDA on a registrational path for TSC‑101, TScan prioritized its heme program, paused enrollment in its solid tumor Phase 1 trial, and implemented a workforce reduction of approximately 30% (66 roles). The company expects a one‑time charge of up to $2.3 million in Q4 2025 and now expects its cash resources to fund operations into the second half of 2027. As of November 7, 2025, shares outstanding were 52,471,405 voting common and 4,276,588 non‑voting common.
TScan Therapeutics (TCRX) filed an 8-K stating it furnished a press release announcing financial results for the quarter ended September 30, 2025. The press release is included as Exhibit 99.1.
The company notes the information is furnished under Item 2.02 and is not deemed filed for purposes of Section 18 of the Exchange Act, nor incorporated by reference into other filings unless specifically stated.
TScan Therapeutics announced a strategic shift to prioritize its hematologic malignancies program and pause further enrollment in its solid tumor Phase 1 trial. The company will focus preclinical work on in vivo engineering for solid tumors and target discovery in autoimmunity. TScan also implemented a workforce reduction of approximately 30%, or 66 roles, and expects a one-time charge of up to $2.3 million in the quarter ending December 31, 2025.
TScan reported alignment with the FDA on the pivotal study design for TSC-101. The company furnished a press release and slide presentation detailing these updates.
TScan Therapeutics, Inc. furnished an updated corporate presentation that it plans to use in meetings with investors, analysts, and other stakeholders. The presentation reflects revised development and operational milestones, including adjusted timelines for its solid tumor program, updates to its pipeline in both hematologic malignancies and solid tumors, and new information on its target discovery work in autoimmunity.
The presentation is attached as Exhibit 99.1 and is also being made available through the company’s investor relations website, although website materials are not incorporated by reference into this report. The materials are furnished under a regulation disclosure item and are not deemed filed for liability purposes under the securities laws.
Dworak Leiden, reporting as an officer (Principal Accounting Officer) of TScan Therapeutics, Inc. (TCRX), filed an initial Form 3 reporting ownership of stock options granted by the company. The Form 3 reflects six option grants exercisable between 04/03/2032 and 01/02/2035 covering a total of 366,925 shares of Voting Common Stock with exercise prices ranging from $1.81 to $6.00. Vesting schedules are described for each grant, generally providing 25% vesting after one year followed by equal monthly vesting over 36 months, with certain tranches tied to service dates or shareholder approval. The filing date for the event is 08/14/2025 and the Form is signed by an attorney-in-fact on behalf of the reporting person.
TScan Therapeutics, Inc. reported a leadership change in its finance organization. On August 14, 2025, the Board appointed Leiden Dworak, the company’s Vice President of Finance, as Principal Accounting Officer, effective the same day. Jason A. Amello ceased serving in that accounting role but continues as Chief Financial Officer and Principal Financial Officer.
Mr. Dworak, age 41, has been Vice President, Finance since April 2022 and previously served as the company’s Principal Accounting Officer from July 2023 to January 2024. He brings 17 years of finance experience in biotechnology and life sciences, including roles at AVROBIO, Moderna, Merrimack Pharmaceuticals, SeraCare Life Sciences, and Boston Scientific, and holds an MBA from Indiana University. The company states there are no family relationships or related party transactions requiring disclosure in connection with this appointment.
Lynx1 Capital Management LP and Weston Nichols filed Amendment No.2 to a Schedule 13G reporting beneficial ownership of 7,857,347 shares of TScan Therapeutics voting common stock, representing 15.0% of the class. The percentage is calculated using 52,314,039 shares outstanding as of May 7, 2025, and the shares are directly held by Lynx1 Master Fund LP.
The cover data shows 0 shares as sole voting or dispositive power and 7,857,347 shares as shared voting and dispositive power. The filing is a Schedule 13G with a certification that the securities were not acquired to change or influence control. The statement is signed by Weston Nichols on behalf of Lynx1 and individually, dated 08/14/2025.
Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, report beneficial ownership of 1,350,000 shares of TScan Therapeutics Voting Common Stock issuable upon exercise of warrants. These shares represent 2.52% of the company's Voting Common Stock based on an aggregate of 52,314,039 shares outstanding used for the calculation. The filing shows shared voting and dispositive power over the 1,350,000 warrant‑issued shares and no sole voting or dispositive power.
This position is reported as holdings through Adage affiliates and reflects potential future dilution if the warrants are exercised; the reported amount is not currently held as sole-owned shares.
TScan Therapeutics reported results for the quarter ended June 30, 2025, reflecting continued investment in its TCR-T therapy pipeline and collaborations. Revenue for the quarter was $3.1 million ( $5.2 million for the six months), driven by research activity under the Amgen collaboration that included a $30 million upfront payment. R&D and G&A increased to $32.6 million and $9.1 million for the quarter, respectively, resulting in a quarterly net loss of $37.0 million (six-month net loss $71.1 million), or $0.28 per share for the quarter.
The company held $169.4 million in cash and cash equivalents and $48.7 million in marketable securities as of June 30, 2025 (totaling ~$218.0 million excluding restricted cash), which management says supports operations into the first quarter of 2027. Long-term debt included a SVB term loan with $32.5 million principal outstanding and an effective interest rate of 8.46%. The filing also highlights regulatory progress with multiple Phase 1 INDs and continued R&D expenditures, alongside disclosed risks and expected ongoing losses.
TScan Therapeutics announced it has furnished a press release reporting its financial results for the quarter ended June 30, 2025. The Current Report states the press release is furnished as Exhibit 99.1 and that the information is furnished, not filed, so it is not subject to Section 18 liability or automatically incorporated by reference into other filings. The filing identifies the company as an emerging growth company and confirms its common stock trades under the symbol TCRX on the Nasdaq Global Market. The report is signed on the company’s behalf by Chief Executive Officer Gavin MacBeath.